• Ascendis Pharma assets rose to EUR 2.43 billion at September 30, 2026, from EUR 1.3 billion at December 31, 2025.
• Total liabilities fell to EUR 926.73 million from EUR 1.47 billion over the same period.
• May's conversion of 2.25% convertible notes due 2028 transferred EUR 719.4 million of liabilities to equity, with no profit impact.
• Deferred tax assets reached EUR 651.89 million, primarily reflecting EUR 679.59 million from reversals of prior-period write-downs.
• Cash and cash equivalents increased to EUR 964.36 million from EUR 616.04 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001612042-26-000024), on November 12, 2026, and is solely responsible for the information contained therein.